<DOC>
	<DOCNO>NCT02633657</DOCNO>
	<brief_summary>The primary objective ass pharmacokinetics ( PK ) gabapentin follow single-dose administration HORIZANT ( Gabapentin Enacarbil ) adolescent ( 13 17 year age ) diagnose moderate-to-severe Primary Restless Legs Syndrome ( RLS ) .</brief_summary>
	<brief_title>A Pharmacokinetic Safety Evaluation HORIZANT ( Gabapentin Enacarbil ) Adolescents With Moderate-to-Severe Primary RLS</brief_title>
	<detailed_description />
	<mesh_term>Restless Legs Syndrome</mesh_term>
	<mesh_term>Gabapentin</mesh_term>
	<mesh_term>gamma-Aminobutyric Acid</mesh_term>
	<criteria>1 . Male female adolescent patient , age 13 17 year , diagnose RLS base IRLSSG consensus criterion , present Appendix 2 . 2 . Total RLS severity score 15 great IRLS rating scale screen . 3 . Body weight great 33.4 kg healthy weight use agebased body mass index ( BMI ) range 5th 85th percentile . Appendix 3 contains BMIforage chart consult . 4 . Negative pregnancy test female childbearing potential . Female patient childbearing potential must agree use one follow acceptable birth control method : 1. intrauterine device place least 3 month prior dose 2. barrier method ( male condom , female condom , diaphragm cervical cap ) spermicide least 30 day prior dose throughout study 3. stable hormonal contraceptive ( include oral , injection , implant ) least 3 month prior dose throughout study Female patient normally abstain sexual activity may recruit provide remain abstinent study , become sexually active , must agree use effective method birth control describe . 5 . Male patient able father child must agree use barrier method ( male condom , female condom , diaphragm cervical cap ) spermicide least 30 day prior dose throughout study . Male patient normally abstain sexual activity may recruit provide remain abstinent study , become sexually active , must agree use barrier method describe . 6 . Signed patient/parent Institutional Review Board ( IRB ) approve informed consent/assent form ( applicable ) prior study procedure . 1 . History allergy , hypersensitivity intolerance HORIZANT gabapentin compound . 2 . Suffering movement disorder could mimic confound accurate diagnosis RLS ( eg , Tourette 's syndrome , tic disorder , periodic limb movement disorder [ PLMD ] , sleep disorder ) . 3 . Currently meet Diagnostic Statistical Manual Mental Disorders Fifth Edition ( DSM5 ) criterion substance use disorder , history thereof , within 12 month prior dose . 4 . Current past history significant psychiatric disorder include limited depression ( treatment antidepressant ) , bipolar disorder schizophrenia . 5 . History suicidal behavior suicidal ideation indicate Columbia Suicide Severity Rating Scale ( CSSRS ) , administer screening ( questionnaire present Appendix 4 ) , per investigator 's judgment . 6 . History seizure disorder increase risk development seizure disorder , include limited complicate febrile seizure history significant head injury . 7 . Medical condition disorder would interfere action , absorption , distribution , metabolism , excretion gabapentin enacarbil , , investigator 's judgment consider clinically significant may pose safety concern , , could interfere accurate assessment safety efficacy , could potentially affect patient 's safety study outcome .</criteria>
	<gender>All</gender>
	<minimum_age>13 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>Restless Legs Syndrome</keyword>
	<keyword>RLS</keyword>
</DOC>